Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report

BACKGROUND: Butorphanol is marketed as a treatment for migraines; however, evidence suggests that the harms of its use exceed the benefits. The short half-life of butorphanol places patients at high risk for opioid dependence and makes tapering a challenge. Buprenorphine/naloxone has unique pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: MacAusland-Berg, Joshua, Wiebe, Amy, Marwah, Radhika, Halpape, Katelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397438/
https://www.ncbi.nlm.nih.gov/pubmed/36017357
http://dx.doi.org/10.1080/24740527.2022.2090911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397438/
https://www.ncbi.nlm.nih.gov/pubmed/36017357
http://dx.doi.org/10.1080/24740527.2022.2090911

Ejemplares similares